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Abstract
RIP140 is a transcriptional coregulator involved in energy homeostasis and ovulation which is controlled at the
transcriptional level by several nuclear receptors. We demonstrate here that RIP140 is a novel target gene of the E2F1
transcription factor. Bioinformatics analysis, gel shift assay, and chromatin immunoprecipitation demonstrate that the
RIP140 promoter contains bona fide E2F response elements. In transiently transfected MCF-7 breast cancer cells, the RIP140
promoter is transactivated by overexpression of E2F1/DP1. Interestingly, RIP140 mRNA is finely regulated during cell cycle
progression (5-fold increase at the G1/S and G2/M transitions). The positive regulation by E2F1 requires sequences located
in the proximal region of the promoter (273/+167), involves Sp1 transcription factors, and undergoes a negative feedback
control by RIP140. Finally, we show that E2F1 participates in the induction of RIP140 expression during adipocyte
differentiation. Altogether, this work identifies the RIP140 gene as a new transcriptional target of E2F1 which may explain
some of the effect of E2F1 in both cancer and metabolic diseases.
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Introduction
RIP140 (Receptor Interacting Protein of 140 kDa also known as
NRIP1) is a nuclear protein of 1158 amino acids, initially
identified as a transcription cofactor of estrogen receptors which,
despite its recruitment in the presence of agonist ligands, exhibits
a strong transcriptional repressive activity of various nuclear
receptors (for a review see [1]). The molecular mechanisms
involved in this transrepression implicate several repressive
domains within the RIP140 molecule and recruitment of different
partners such as HDACs and CtBPs. Several post-translational
modifications (such as acetylation, methylation and conjugation to
SUMO peptides or vitamin B6) also play key roles in the
regulation of RIP140 activity [2-3]. Interestingly, we previously
demonstrated that RIP140 was involved in several transcriptional
regulatory loops since its expression was increased upon estrogen
or androgen stimulation, in breast [4] and prostate [5] cancer cells,
respectively. Cloning of the human [6] and mouse [7] RIP140
genes showed that the overall organization was conserved and
allowed identification of several cis-acting elements involved in
transcriptional regulation by estrogens and dioxin [6] or by the
nuclear receptor ERRa [7].
Molecular and cellular analyses together with in vivo approaches
using knock-out mice have highlighted the role of RIP140 in
various physiological and pathological processes [8]. For instance,
this gene is required for a proper oocyte release during ovulation
and involved in the regulation of fat accumulation and energy
homeostasis in metabolic tissues. We recently reported that its
expression is significantly decreased in basal-like breast cancers as
compared to luminal ones [9]. We also demonstrated that RIP140
is involved in the control of cell proliferation and that it negatively
regulated the activity of E2Fs [9].
The E2F family represents a class of transcription factors which
regulate a broad spectrum of genes involved in major cellular
processes such as DNA replication, apoptosis, differentiation and
cell cycle [10]. E2F1, the founding member of the E2F family, has
been shown to possess oncogenic properties and numerous
evidences show that deregulation of E2F activity plays a key role
in tumorigenesis [11-12]. In addition to its effect on cell cycle
progression, E2F1 can also induce apoptosis through p53-de-
pendent and -independent mechanisms [13] and data indicate that
E2F1 behaves as a tumor suppressor in vivo [10]. More recently,
a clear implication of E2F1 has been demonstrated in different
metabolic processes including lipid and adipocyte metabolism or
glucose homeostasis (for a review see [14]).
Eight E2F genes have been identified in mammals which
encode proteins classified as transcriptional activators (E2F1–3) or
repressors (E2F4–8) [15]. Most of the E2F family members exhibit
structural conserved features such as a DNA-binding domain and
hydrophobic heptad repeats which allow heterodimerization with
DP proteins (DRTF1 polypeptides DP1, DP2 and DP3) through
coil-coil interactions. In their C-terminus moiety, E2F1 to 5
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by different post-translational modifications (such as phosphory-
lation and acetylation) and through the binding of pocket proteins
(pRB, p107 and p130). E2F transcriptional activity is controlled by
a plethora of factors [16]. The association with pocket proteins
allows active repression through the recruitment of histone
deacetylases and methyltransferases and is finely regulated by
various members of the cyclin/cdk family [17].
The present study further deciphers the role of RIP140 in the
E2F signaling pathway. Our data identify the RIP140 gene as
a novel transcriptional target of E2F1 that might be involved in
a wide range of pathological processes regulated by this
transcription factor such as cancer or metabolic diseases.
Materials and Methods
Plasmids and Reagents
The pcDNA3-E2F1 and 4, pCMV-DP1, pCMV-Rb expression
vectors were given by Dr C. Sardet (IGMM, Montpellier, France)
and the pCMV-E2F2, 3, 5 and E2F6 expression vectors by Dr K.
Helin (European Institute of Oncology, Milan, Italia). The
reporter plasmids (CyclinE-luc and (E2F)3-TK-Luc) were obtained
from Dr L. Fajas (IRCM, Montpellier). The pEFc-mycRIP140
expression vectors and the plasmid containing the RIP140
promoter (RIP900) have been described previously [6]. The
pRL-CMVBis plasmid expressing Renilla luciferase (Stephan
Vagner, Toulouse, France) was used to normalize transfection
efficiency. The deletion of the Sp1 interaction domain in the
pCDNA3 E2F1 sequence (from residues 109 to 121) [18] and the
mutation in the DNA-binding domain (E132) [19] were done
using the QuickChange XL kit (Stratagene). The same protocol
was used to generate DP1 mutants in the pCMV expression vector
(DP1 D107–126 and DP1 D205–277) corresponding respectively
to the deletion of the DNA-binding [20] or E2F1 [21] interaction
domains.
Bioinformatics
Localization of human [6] and mouse [7] NRIP1 promoters
(GenBank accession numbers AF127577 and AC145744 re-
spectively) have been described previously. Potential transcription
factor binding elements in the promoter region of both promoters
were searched using Genomatix MatInspector Program (www.
genomatix.de). Alignment of human and mouse NRIP1 promoter
sequences and identification of the evolutionary conserved
transcription factor binding elements were performed using
Genomatix DiAlign Program (www.genomatix.de).
Cell Culture
MCF-7 and HeLa human cancer cell lines were purchased from
the American Type Culture Collection and routinely maintained
in the laboratory as previously described [9]. For synchronization,
2610
6 cells HeLa cells were grown in 100 mm culture dishes to
60% of confluence in medium containing 0.5% FCS (serum
starvation) and 2 mM HU (Boehringer Mannheim) was added
during 24 hr to induce cell synchronization. When cells were at
80% of confluence, medium was removed to release the block. At
each time point, cells were washed, trypsinized and total RNA was
extracted. Cell cycle analysis was performed using a FACs-
Vatange flow cytometer (Becton-Dickinson, San Jose, CA). For
each sample, 2.10
4 events were collected and the CellQuest
software was used to analyze the list-mode data. ModFit software
was used to determine the percentage of each G0/G1, S and G2/
M phase in the population.
Gel-Shift Assay
Gel shift assays were performed as previously described [6].
Sequences of sense strand oligonucleotides are given in Table S1.
Where indicated, anti-E2F1 antibody (Ab) was added in the
incubation mixtures, 5 min before the radioactive probe. Com-
plexes were separated 15 min. later on non denaturing 4.5%
polyacrylamide gel electrophoresis (acrylamide/bisacrylamide,
29:1) in 0.256 Tris borate-EDTA at 150 V for 2 h, gel-fixed in
40% methanol/10% acetic acid, dried, and exposed overnight.
ChIP Analysis
For ChIP analysis, MCF-7 cells (70% confluent) were cross-
linked with 3,7% formaldehyde during 10 min at 37uC. The
ChampionChIP One-Day Kit (SABiosciences) was then used
according to the manufacturer’s recommendations. Immunopre-
cipitations were performed using the KH95 (sc-251 SantaCruz),
C-20 (sc-866 Santa-Cruz) or 2656C6a (sc-81370 Santa-Cruz)
antibodies against E2F1, E2F4 and RIP140 respectively. It
should be noted that although the anti-E2Fs antibody were given
by the supplier as being specific, we could not eliminate with
certainty the possibility that they may cross-react with other
E2Fs. As a negative control, we performed IP with no antibody
(in our hands, such IP controls gave the same background as an
isotype-matched mAb). Quantitative PCR was then performed
using the Power SYBR Green PCR master mix, on an Applied
Biosystems 7300 thermal cycler with 2 ml of material per point.
Primers flanking the E2F site of the RIP140 and cyclin A2
promoters are given in Table S1. The input DNA fraction
corresponded to 1% of the immunoprecipitation.
Transient Transfection and Luciferase Assays
MCF-7 cells were plated in 96-well plates (20,000 cells per well).
24 h later, plasmid tests containing firefly luciferase reporter gene
(25 ng), pRLCMVBis (25 ng per well) used as internal standard,
and 25 ng each of different factors (E2F1, 2, 3, 4, 5, 6 and DP1)
and 200 ng each of either RIP140, pRb, p130 proteins to a total of
0.25 mg total DNA per well, were cotranfected using Jet-PEI. 48 h
after transfection, cells were lysed and firefly luciferase values were
measured and normalized with the Renilla luciferase activity; all
triplicate point values were expressed as mean + SD.
Western-blot Analysis
Expression plasmids for E2F1, 2, 3, 4 or DP1 were transfected
in MCF-7 cells using JetPEI. After cell lysis in 25 mM Tris-HCl,
pH7.8, 2 mM EDTA, 2 mM DTT, 10% Glycerol, 1% Triton,
supplemented with protease inhibitors, whole cell extracts were
diluted in Laemmli sample buffer 2X and resolved by SDS–
PAGE. Western blotting detection was performed using primary
antibodies against E2Fs (sc-251, sc-9967, sc-56665, sc-1082 for
E2F1, 2, 3, 4 respectively and sc-53642 for DP1 from Santa-Cruz
Biotechnology). To check for gel loading, we used the anti-actin
(A2066 from Sigma) or anti-TBP (MA1-21516 from Thermo-
Scientific) antibodies.
RNA Extraction and Quantitative PCR
Total RNA was extracted from cells as previously described [9].
PCR were carried out in a final volume of 10 ml using 0.5 mlo f
each primer (shown in Table S1) (10 mM), 2 ml of the supplied
enzyme mix, 4 ml of H2O, and 3 ml of the template diluted at
1:20. After a 10 min preincubation at 95uC, runs corresponded to
45 cycles of 15 s each at 95uC, 7 s at 57uC and 15 s at 72uC.
Melting-curves of the PCR products were analyzed using the
LightCycler software system to exclude amplification of unspecific
E2F1 Controls RIP140 Expression
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gene) and normalized to a calibrator sample.
Adipocyte Differentiation Experiments
E2F1
2/2 and wild-type mouse embryonic fibroblasts (MEFs)
were isolated from 13.5 days-old embryos in compliance with the
French guidelines for experimental animal studies (agreement
B34-172-27). Three different MEF cultures were obtained from
E2F1 wild-type and knock-out embryos and grown in F12-DMEM
supplemented with 10% fetal calf serum and 1.5% HEPES. For
adipocyte differentiation experiments, MEFs (at passage 3) were
seeded in 6-well plates. Two days after confluence, differentiation
was induced by treating cells for 2 days with a cocktail containing
0.5 mM IBMX (3-isobutyl-1-methylxanthine), 10 mg/mL insulin,
1 mM dexamethasone and 1 mM BRL49653. Every two days,
medium was changed with F12-DMEM, 10% serum, 1.5%
HEPES, 10 mg/mL insulin and 1 mM BRL49653. Differentiated
cells were visualized with Oil Red O staining (Sigma). Nuclear
protein extracts were prepared using the NE-PER kit (Thermo
Scientific) and 20 mg of nuclear cell extracts were analyzed by
Western blotting using primary antibodies against E2F1 (sc-193
from Santa-Cruz Biotechnology) and RIP140 (H300 from Santa-
Cruz Biotechnology). Total RNA was extracted using the Quick-
RNA Miniprep (Zymo Research) and 1 mg was analyzed for
RIP140 mRNA levels by real-time quantitative Polymerase Chain
Reaction on an Applied Biosystems 7300 thermal circler. Results
were corrected for RS9 mRNA levels used as a reference gene.
Statistics
Statistical analysis was performed using the Student t test except
for Figure S1 where we used the paired t-test (*p,0.05,
**p,0.005 and ***p,0.0001).
Results
Identification of Bona Fide E2F Binding Sites in the RIP140
Promoter
We previously reported the cloning and characterization of the
human RIP140 gene promoter with the identification of various
response elements [6]. Upon close inspection of the proximal
promoter region, we mapped several putative E2F binding sites
resembling the consensus sequence TTTSGCGCS. In the human
RIP140 promoter, these sites were located at 2637, 2417, 2146,
221 and +98 bp from the 59 extremity of the cDNA (Figure 1A
and B). These sites spread into two clusters with sites a and b being
in the distal part of the promoter and sites c, d and e around the
transcription start site, all being flanked by putative Sp1 sites. It
should be noted that the E2Fa site exhibited the sequence which is
the closest to the consensus motif with only one nucleotide change
and that the E2Fe site was in fact a composite site with three
different possibilities to bind the E2F/DP heterodimers
(Figure 1A). Interestingly, the murine RIP140 promoter contains
four putative E2F binding sites, the E2Fd site being perfectly
conserved in term of position and sequence as compared to the
human promoter (Figure 1 B and C).
We then checked the ability of the five different sites from the
human promoter to act as bona fide E2F binding sites. Using gel
shift experiments, we demonstrated that E2F1 strongly interacts
with oligonucleotides encompassing some of the putative binding
sites (i.e. E2Fa, E2Fd and E2Fe). As shown in Figure 2A, specific
retarded bands (marked with an asterisk) were obtained when the
labeled target sequence was incubated with increasing amounts of
whole cell extract prepared from cells overexpressing E2F1 and
DP1. The effect was comparable to that obtained with a consensus
E2F binding site from the adenovirus gene (Ad2E2F) and these
retarded bands were all shifted with an anti-E2F1 antibody. In
these experiments, we found that the apparent binding affinities of
E2F1/DP1 for the different motifs ranked as follows E2Fa.E2F-
d=E2Fe (Figure 2B). No significant binding was observed for
E2Fb and c (Figure 2A) and point mutations known to abolish E2F
binding indeed hampered the interaction both in direct gel shift
assays and in competition experiments (data not shown).
In order to demonstrate that the interaction of E2F1/DP1 also
occurred in intact cells, we performed chromatin immunoprecip-
itation experiments. As shown in Figure 2C, the regions of the
RIP140 promoter encompassing the E2Fa or E2Fd binding sites
were PCR amplified at higher levels after immunoprecipitation
with the anti-E2F1 antibody as compared to background levels of
amplification of the same region after immunoprecipitation in the
absence of the relevant antibody. The signal obtained after
amplification of the RIP140 promoter was comparable to that
obtained with the well-known E2F-target gene cyclin A2.
Altogether, these data strongly suggested that the RIP140 gene
could be an E2F target.
Regulation of the RIP140 Promoter by E2Fs
To demonstrate a transcriptional regulation of the RIP140
promoter by E2Fs, we transiently transfected MCF-7 breast cancer
cells with the RIP900 reporter construct containing the 900 bp of
the RIP140 promoter fused to the luciferase coding sequence. This
construct (which encompassed the five E2F binding sites that we
identified) was cotransfected with expression vectors encoding the
different members of the E2F family (Figure 2D and Figure S1).
When cotransfected with DP1, we found that E2F1, E2F2 and
E2F3 strongly increased luciferase activity from the RIP900
reporter (2.5 to 7-fold). Western-blot analysis confirmed the
overexpression of the different E2Fs and that of DP1 (see Figure
S3B and C). As expected increasing concentrations of expression
vectors for E2F1 and DP1 produced a clear dose-dependent
induction of luciferase activity on both the human and murine
RIP140 reporters (data not shown). By contrast, E2F4, E2F5 and
E2F6 were not able to transactivate the RIP140 promoter as
expected since these factors are considered as transcriptional
repressors. As shown in Figure 2D, we observed a significant
decrease (1.6 to 3-fold; p,0.001) in luciferase activity when E2F4–
6 were overexpressed.
Regulation of Endogenous RIP140 Expression
To strengthen our results on the transiently transfected RIP140
promoter, we analyzed the regulation of the endogenous RIP140
mRNA upon overexpression of E2F1 and DP1 by transient
transfection. As shown in Figure 3A, this led to a significant
increase in the levels of RIP140 mRNA comparable to that of
cyclin D1 measured in parallel, thus confirming that RIP140 is
a transcriptional target of E2F1.
As a consequence of the transcriptional control by E2Fs, the
RIP140 gene expression might be regulated during cell cycle
progression. To test this hypothesis, we performed cell synchro-
nization using hydroxyurea and measured, by quantitative RT-
PCR, the expression of RIP140 mRNA after release of the block
(Figure 3B). Cell synchronization was monitored by FACS analysis
(data not shown) and quantification of cyclin E and cyclin B1
mRNA levels peaking respectively at the transitions between G1
and S and between S and G2/M (Figure 3B). Very interestingly,
our data indicated that, in such experiments, the accumulation of
RIP140 mRNA varied more than 5-fold, with two peaks of
accumulation at 4 and 14 hr after the block release which matched
perfectly with the transient increases of cyclin E and B1 mRNAs
E2F1 Controls RIP140 Expression
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e35839Figure 1. Localization of putative E2F binding sites in the RIP140 promoter. (A) Sequence of the human RIP140 gene promoter region. (B)
Schematic representation of human and mouse RIP140 promoters. The human and mouse promoters exhibit 4 to 5 potential E2F binding sites (grey
square) with a conserved distribution. Bioinformatics analysis also identified Sp1 binding sites (white square) in the murine (6 Sp1 sites) and in the
E2F1 Controls RIP140 Expression
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cell-cycle regulated gene in human cancer cells.
Localization of the Regulatory Elements
Using promoter mutagenesis (deletion and point mutations), we
then defined the cis-acting elements required for the positive
regulation by E2Fs. In a first step, we generated mutants of the
RIP140 promoter with point mutations in the different E2F
response elements (Figure 4A). When we analyzed the effect of
each individual mutation (Figure 4B, left panel), we found that
mutation of the E2Fa site slightly increased the response whereas
mutation of the E2Fe site decreased the response to E2F1/DP1
overexpression. Surprisingly, a construct with mutation of the five
E2F response elements (E2Fnull) was still significantly regulated by
E2F1/DP1 to a level comparable to that obtained with the mE2Fe
reporter.
We then analyzed reporter transactivation when a single
functional E2F response element was left intact (Figure 4B, right
panel). When compared to the promoter mutated on the five E2F
response elements, we found that the E2Fb site was not functional
whereas all the other sites produced a significant transactivation,
the highest effect being obtained with the E2Fe site. Interestingly,
this construct even supported a significantly higher transactivation
by E2F1/DP1 than the wild-type reporter (compare left and right
panels). Altogether, these data suggested 1) that other cis-acting
elements than these five E2F binding sites mediate the regulation
of the RIP140 promoter by E2Fs and 2) that the distal (E2Fa) and
proximal (E2Fe) response element support opposite regulation by
E2Fs (negative and positive effects, respectively).
Deletion analysis of the promoter confirmed these data
(Figure 4C, Figure S1A and B). Indeed, the regulation by
E2F1/DP1 was stronger with the DPAc construct which lacks
only the E2Fa site, thus confirming a negative effect of this E2F
response element. Moreover, the DPSc reporter construct which
encompasses only the E2Fd and E2Fe sites exhibited the same
regulation than the wild-type RIP900 construct confirming that
the proximal region of the promoter was sufficient to mediate the
regulation by E2Fs. However, although mutations of the two sites
(E2Fd and e) in the DPSc reporter construct reduced the
regulation of luciferase activity in response to E2F1/DP1
(Figure 4D), the DPSc reporter construct with the double
mutation was still transactivated by E2F1/DP1 again suggesting
that other mechanisms are involved.
Role of DP1 and Sp1 Transcription Factors in the
Regulation by E2Fs
E2F transcription factors are believed to act as heterodimers
with DP proteins which are ubiquitously expressed [22]. When we
overexpressed only E2F1 (Figure 5A - black boxes), we observed
a significant level of transactivation of the RIP140 promoter which
might reflect the action of E2F1 as heterodimers with endogenous
DP proteins. Similar transactivation upon overexpression of E2F1
only was also obtained for the cyclin E promoter. However, we
found that coexpression of DP1 did not produce the same effect on
the transactivation by E2F1 on the two promoters. Indeed,
whereas we noticed an increase in the transactivation of the cyclin
E reporter, DP1 expression vector cotransfection produced
a strong inhibitory effect on the regulation of the RIP140
promoter by E2F1 (Figure 5A and Figure S1C).
To extend this observation, we performed similar transfection
experiments on other E2F-target promoters i.e. the DHFR and
ARF promoters. Interestingly, the negative effect observed with
DP1 overexpression on the RIP140 promoter was also observed
with the ARF promoter but not with the DHFR promoter
(Figure 5B). As shown in Figure 5C, this effect of DP1 was also
detected with the DPSc reporter construct and required the
presence of the E2F binding sites since the inhibition by DP1 was
strongly decreased with the DPSc reporter harboring a mutation of
the E2Fd and e sites.
We then used different mutants of DP1 to further decipher the
mechanisms involved in this effect. When DP1 is impaired in its
ability to bind DNA (D107–126 mutant) [20] or to heterodimerize
with E2F1 (D205–277 mutant) [21], we no longer observed the
inhibitory effect of the transactivation by E2F1 on the RIP140
promoter (Figure 5D). By contrast, the two DP1 mutants exhibited
a slight inhibitory effect on the cyclin E promoter when compared
to the wild-type DP1. These data suggested that forcing
heterodimerization of E2F1 with DP1 reduced the transcriptional
response of the RIP140 promoter.
Altogether, the results from promoter mutagenesis combined to
the atypical effect of DP1 overexpression strongly supported
a complex regulation of the RIP140 promoter by E2F1 involving
for instance a combination of direct and indirect recruitment. One
hypothesis for an indirect recruitment of E2F1 on the RIP140
involved Sp1 transcription factors. Indeed, several studies have
reported a physical interaction and a transcriptional synergism
between E2F1 and Sp1 [23]. The proximal region of the RIP140
promoter encompasses several functional Sp1 binding sites (see
Figures 1B and 5E and [6]). We therefore introduced point
mutations in the DPSc reporter construct which targeted the
different Sp1 sites. As shown in Figure 5E, disruption of sites 6/7
totally abolished the regulation by E2F1 (with or without
coexpression of DP1) whereas mutation of the Sp1 site 8 was
ineffective. To further emphasize the role of Sp1 in the regulation
of the RIP140 promoter by E2F1, we generated a mutant of E2F1
lacking the region from residue 102 to 125 which mediates its
interaction with Sp1 [18]. When compared to wild-type E2F1, this
mutant transactivated to the same extend when DP1 was
cotransfected (i.e. when heterodimerization was forced) but was
significantly less efficient to activate transcription from the RIP140
promoter when overexpressed alone i.e. when Sp1-mediated
transactivation took place (Figure 5F). Same results were obtained
on the proximal promoter region of the RIP140 gene using the
DPSc reporter construct (data not shown). Altogether, this
indicated that the positive regulation of the RIP140 promoter by
E2F1 involved the proximal region spanning from nucleotides
2140 to +100. This regulation implicated a classical recruitment
of E2F1 (mainly through the E2Fe site) and an indirect
recruitment or a stabilization of this binding via Sp1.
Existence of a Negative Regulatory Loop Involving
RIP140 and E2F1
We and others (see [1] for a review) previously reported that
RIP140 was engaged in several negative feedback regulatory loops
involving various nuclear receptors. We also recently described the
inhibitory role of RIP140 in the regulation of E2F1 activity [9].
Since our above-mentioned results demonstrated that E2F1 was
a potent regulator of RIP140 expression, we investigated whether
RIP140 could in turn control its own activation by E2F1. As
human promoters (8 sites in two clusters). (C) Alignment of the different putative E2F binding sites found in the human and mouse promoters with
the consensus sequence.
doi:10.1371/journal.pone.0035839.g001
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e35839Figure 2. Analysis of E2F1 binding on the RIP140 promoter. (A) Electromobility shift assay was used to analyze E2F1/DP1 binding on the
adenoviral E2F response element (Ad2E2F) or on the E2Fa, b, c, d and e sites of the RIP140 promoter (viewed in Figure 1). Asterisks indicate the
retarded bands which contain E2F1. (B) Dose response experiment using increasing amounts of E2F1/DP1 on E2Fa, d and e binding sites. (C) ChIP
experiments using immunoprecipitation (IP) of E2F1 on the E2Fa and E2Fd sites of the human RIP140 promoter. The cyclin A2 promoter was used as
a positive control. Data are expressed as percent of the PCR signal obtained with the amount of chromatin used for IP (input). Negative control of IP
was performed without any antibody which, in our hands, gave the same background as an isotype-matched mAb. Statistical analysis was performed
using the Student t test (*p,0.05 and **p,0.005). (D) Human RIP900-luc (25 ng), E2F1 to 6 (25 ng) and DP1 (25 ng) were overexpressed in the
indicated combinations. Relative luciferase activity was normalized with renilla luciferase activity as described in Materials and Methods. The values
shown are from a representative experiment out of 3 data sets. They are expressed as a percentage of the activity obtained with control and are the
mean (6SD) of triplicate. Statistical analysis performed using the Student t test (**p,0.005 and ***p,0.0001). (E) MCF-7 cells were transiently
transfected with the human and murine RIP140 promoter reporter plasmids (25 ng) together with expression vectors for E2F1, DP1 (25 ng each).
Results were expressed as described in panel D and a representative experiment is shown (n=7).
doi:10.1371/journal.pone.0035839.g002
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the transactivation of its own promoter by E2F1 either when
overexpressed alone or in combination with DP1. Using chroma-
tin immunoprecipitation, we confirmed the presence of RIP140 on
the region of its own promoter which encompasses the distal E2Fa
binding site. As shown in Figure 6B, the signal obtained after
immunoprecipitation of RIP140 was even stronger than that
obtained on the cyclin A2 promoter. In parallel, we compared the
regulation of E2F1 transactivation by RIP140 or pRb both on the
RIP140 and cyclin E promoters. As shown in Figure 6C, we found
that pRb was significantly more potent than RIP140 to inhibit
E2F1 activity on both reporters, except on the cyclin E promoter
in the presence of E2F1 alone.
Effect of E2F1 Knock-out on RIP140 Expression during
Adipocyte Differentiation
Inadditiontothecontrolofcellproliferationandapoptosis,E2F1
hasrecentlybeenshowntoplaycriticalroleinmetaboliccontroland
inparticulartopositivelyregulatesadipogenesis[14].Forinstance,it
has been reported that lipid incorporation is decreased in E2F1
knock-out MEFs stimulated to differentiate into adipocytes [24].
RIP140 is also a key regulator of fat metabolism [25] and,
interestingly,bothE2F1[24]andRIP140[26]expressionincreased
during the differentiation process, E2F1 being induced earlier than
RIP140. In order to determine whether E2F1 participates in the
regulation of RIP140 expression during adipocyte differentiation,
we stimulated both E2F1 wild-type and knock-out MEFs to
differentiate in vitro in response to hormone stimulation.
As shown in Figure 7A and as expected, E2F1 expression
transiently increasedduring differentiation (peakafter 2days) and is
totally lost in E2F1 knock-out mice. In addition, differentiation
followed by Oil Red O staining to detect lipid droplets was
significantlyreducedinE2F1knock-outMEFsascomparedtoE2F1
wild-type cells. We quantified RIP140 mRNA levels in parallel and
observed a peak of expression at day 7 post-differentiation as
previously described [26]. Importantly, RIP140 mRNA accumula-
tion was significantly reduced in knock-out cells supporting a role of
E2F1 in the control of RIP140 expression (Figure 7B).
Discussion
RIP140 was initially characterized as a transcriptional coregu-
lator of ligand-activated nuclear hormone receptors, involved in
the control of ovarian functions and metabolic pathways (for
a review, see [27]). In the present study, we identified RIP140 as
a novel cell-cycle regulated gene whose expression is directly
controlled by E2F transcription factors.
Based on in vitro DNA-protein interaction assays, ChIP
experiments and transient transfection assays, our data clearly
demonstrate that E2F1 (as well as other activating E2Fs) increase
transcription from the RIP140 promoter through binding to the
proximal promoter region. Several evidences (mutagenesis of Sp1
response elements and use of an E2F1 mutant defective for Sp1
binding) strongly supported the involvement of Sp1 transcription
factors in the regulation of RIP140 by E2F1. In addition, the use
of mithramycin which has been described as an inhibitor of Sp1
binding to DNA [28] also inhibited the regulation of the RIP140
promoter by E2F1 (data not shown).
The interaction between Sp1 and E2F1 has been previously
demonstrated in vitro and by coimmunoprecipitation [29–30] and
amino acids 102–125 of E2F-1 and 622–668 of Sp1 appeared
sufficient for interaction of the two proteins [18]. Interestingly, it
has been reported that the expression of the SRC3 gene (which
encodes a transcriptional coregulator of both nuclear receptors
[31] and E2F1 [32]) was also controlled by E2F1 acting via Sp1
sites [33]. Interestingly, using ChIP-chip assays and high density
oligonucleotide tiling arrays, Bieda et al. have shown that the great
majority of E2F1 binding sites are in CpG islands (which are
highly enriched in Sp1 sites) and lack the consensus binding site
motif [34]. It is therefore possible that on the RIP140 promoter,
Sp1 not only synergizes with E2F1 but directly participates in the
Figure 3. Regulation of the endogenous RIP140 gene. (A) The
levels of E2F1, cyclin D1 and RIP140 mRNAs were measured in MCF-7
cells 2 days after transient transfection with plasmids allowing the
overexpression of the E2F1/DP1 heterodimer. Statistical analysis was
performed using the Student t test (***p,0.0001). (B) HeLa cells were
synchronized by 2 mM hydroxyurea (HU) and, after block release the
distribution of cells in G1, S and G2/M was analyzed by flow cytometry
(upper panel). Cyclin B1 and E, and RIP140 mRNA levels were quantified
by real-time quantitative RT-PCR as described in Materials and Methods
(lower panel). The results are expressed in arbitrary units after
normalization by RS9 mRNA levels. Values are the means 6 S.D. of
three independent experiments.
doi:10.1371/journal.pone.0035839.g003
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expression of E2F1 impaired in its ability to bind DNA (E132
mutant) [19] resulted in a dramatic decrease in transactivation of
the RIP140 promoter in the absence or presence of overexpressed
DP1 (Figure S2) suggesting that the DNA-binding domain of E2F1
could be required for both direct and indirect recruitment on the
RIP140 promoter. This is in agreement with the fact that the
DNA-binding region of E2F1 overlaps in part with the domain
which binds to Sp1 [18].
An indirect recruitment of E2F1 is supported by our observation
highlighting the repressive role of DP1 overexpression in the
regulation of RIP140 promoter. This effect is also observed with
the mouse RIP140 promoter (Figure S3A) and appears restricted
to certain promoters since it was also observed on the ARF
promoter construct but not with other promoters such as cyclin E
Figure 4. Importance of the proximal region of the RIP140 promoter. (A) Schematic representation of the RIP140 promoter sequence
(RIP900 plasmid) showing the E2Fs binding sites (a, b, c, d and e, indicated with grey ovals), the Sp1 binding sites (open circles) and the different 59
deletion mutants (DPAc, DPPc and DPSc). (B) MCF-7 cells were transiently transfected with the human RIP140 promoter reporter plasmids (25 ng)
containing mutations of the E2Fs binding sites together with expression vectors for E2F1 and DP1 (25 ng each). In the left panel, each mutant has
one E2F site mutated (mE2Fa, b, c, d and e) or multiple mutations which abolish all sites (E2Fnull). In the right panel, only the indicated site remains
intact (E2Fa, b, c, d and e). (C and D) The same experiments as above were repeated with deletion mutants (respectively DPAc, DPPc, DPSc) of the
RIP140 promoter (C) or with the proximal promoter region (mutant DPSc) with point mutations of the E2F binding sites (mE2Fd and e) (D). All results
were expressed as described in Figure 2D and representative experiments are shown (n=3).
doi:10.1371/journal.pone.0035839.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e35839Figure 5. Effect of DP1 and Sp1 on the transactivation by E2F1. (A) MCF-7 cells were cotransfected respectively with the human RIP140 and
cyclin E promoter reporter plasmids (25 ng) together with E2F1 (25 ng) and increasing dose of DP1 factors (0, 5, 25, 50 ng) (left). Results were
expressed as in Figure 2D (n=4). (B) The human RIP140, ARF and DHFR promoter reporter plasmids were tested with E2F1+/2 DP1. The luciferase
activity with E2F1 alone overexpressed was normalized at 100% (n=3). (C) Different mutants of the RIP140 promoter (hRIP900wt, DPScwt, mE2Fde)
were tested for the response to overexpression of E2F1+/2 DP1. Results were expressed as in Figure 5B (n=4). (D) The effect of two deletion mutants
of DP1 protein (DP1 D107–126 that abolishes DNA binding and D205–277 for E2F binding) on E2F1 activity was measured on hRIP140 and cyclin E
promoters. Results were expressed as in figure 2D (n=3). (E) MCF-7 cells were transiently transfected as indicated in Materials and Methods, with the
point mutants for Sp1 binding sites (#6/7 or #8 shown in Figure 3A) of the proximal sequence DPSc reporter plasmid (25 ng) together with
expression vectors for E2F1+/2 DP1 (25 ng each). Results were expressed as in Figure 2D (n=3). (F) E2F1 mutated for Sp1 interaction (E2F1DSp1)
was used +/2 DP1 on the proximal promoter region (DPSc reporter plasmid), in the same conditions as above. Results were expressed as in Figure 2D
(n=3).
doi:10.1371/journal.pone.0035839.g005
E2F1 Controls RIP140 Expression
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e35839or DHFR, thus emphasizing the specificity of this regulation. This
observation is reminiscent of previous work showing that upon
DP1 knock-down in cells, the expression of some E2F-target genes
such as PCNA and MCM3 is not inhibited [35]. The use of DP1
mutants indicates that both the DNA-binding domain and the
heterodimerization interface were required to achieve this
regulation. The reduced transcriptional response of the RIP140
promoter to E2F1 when DP1 is overexpressed may thus result
from a forcing of E2F1 heterodimerization and/or direct
competition of DP1 with Sp1 for the interaction with E2Fs, both
leading to a decreased synergism between the latter partners.
Altogether, our in vitro results clearly demonstrate that RIP140 is
a direct target of E2F1. This conclusion is reinforced by our data
demonstrating that the accumulation of RIP140 mRNA varies
during cell cycle progression although it remains to be demon-
strated whether E2Fs are involved in the two peaks of RIP140
expression observed in synchronized cells at the G1/S and G2/M
transition. This is conceivable since recent data from Nevins’
laboratory clearly demonstrated that E2Fs are key actors in gene
regulation during the G2/M transition [36]. Indeed, the analysis
of the G2-regulated cdc2 and cyclin B1 genes revealed the
presence of both positive- and negative acting E2F response
Figure 6. Repression of E2F transactivation by RIP140 and pocket proteins. (A) The human WT RIP900-luc reporter plasmid (25 ng) and
E2F1+/2 DP1 (25 ng each) were transiently transfected in MCF-7 cells with a dose response of RIP140 expression plasmids (0, 50, 100 or 200 ng). (B)
ChIP experiments using immunoprecipitation (IP) of E2F1 and RIP140 on the E2Fa site of the human RIP140 promoter. The cyclin A2 promoter was
used as a positive control. Data are expressed as percent of the PCR signal obtained with the amount of chromatin used for IP (input). Statistical
analysis performed using the Student t test (***p,0.0001 and *p,0.05). (C) MCF-7 cells were transfected with human RIP900-luc or cyclin E-luc
reporter plasmid (25 ng), with E2F1+/2 DP1 (25 ng) and pocket proteins Rb or RIP140 expression vectors (200 ng or 250 ng) in 96 well plates in the
indicated combinations. Results were expressed as in Figure 2D (n=4).
doi:10.1371/journal.pone.0035839.g006
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repressors). A similar implication of different E2F elements,
binding to distinct E2Fs and relaying positive or negative
regulation of transcription, has been reported for the E2F1
promoter [37]. Data presented in Figure 4B, 4C and S1C
indicated that deletion or mutation of the distal site E2Fa in the
RIP140 promoter leads to a stronger induction by E2F1/DP1. As
shown in Figure S4, E2F4 is able to interact with the E2Fa site in
gel shift assay (panel A) and in ChIP experiments (panel B), the
interaction being even stronger than that obtained with E2F1.
Moreover, the deletion of the distal region of the RIP140
promoter which encompassed the E2Fa site (DPAc reporter
construct) significantly decreased the repression of E2F1 transacti-
vation by E2F4 (Figure S4C). Altogether, this suggests that the
distal E2F response element might play a role in the regulation of
the RIP140 promoter by E2Fs by preferentially recruiting
repressive E2Fs such as E2F4.
Interestingly, a bioinformatic analysis was conducted on the
RIP140 promoter sequence using six different species (namely
Homo sapiens, Pan troglodytes, Bos Taurus, Oryctolagus cuniculus, Mus
musculus and Rattus norvegicus). As shown in Figure S5, data indicated
that the response elements which are the best conserved during
evolution, are those that we found to be the most relevant from
a functional point of view. Indeed, the Sp1 sites #6–7 and the
E2Fd site are perfectly well conserved in the six different species.
By contrast, the other binding sites, namely E2Fb, E2Fc and E2Fe,
are very poorly conserved. It should be noted that the E2Fa site is
well conserved in 3 species and that an upstream site is detected at
2877 in mouse and rat supporting the functionality of this distal
site that we evidenced in the human promoter based on mutation
analysis (see Figure 4B and C).
We and others previously reported that several nuclear receptors
(such as ERa [6], AR [5] and RARa [38]) or other transcription
factors (such as AhR [6]) positively regulate RIP140 mRNA levels,
thus evidencing the existence of several negative feedback loops.
Such a regulatory loop also exists with E2F1 whose transcriptional
activity is negatively regulated by RIP140 on various promoters [9]
and also on the RIP140 promoter itself (Figure 6). The RIP140
gene is therefore controlled both by ERa and E2Fs thus extending
the list of coregulated genes (CDC6, CDC25A, PCNA, POLA2,
RFC4, SMC2, PRC1) and confirming a previous observation
made by the Mader’s laboratory which reported that one of the
most enriched binding sites in up-regulated estrogen target genes is
that for E2F transcription factors [39].
From a more physiological point of view, E2F1 has been
described as a multifaceted transcription factor which can both
Figure 7. Regulation of RIP140 mRNA levels in E2F1 knock-out mice. (A) Adipocyte differentiation of mouse embryo fibroblasts. At different
times of adipocyte differentiation, lipid accumulation was measured by Oil Red O staining in wild-type (WT) and E2F1
2/2 MEFs. The levels of E2F1
protein were detected by western-blot analysis as described in Materials and Methods and loading control was performed using an anti-TBP antibody.
Time 0 corresponds to the addition of the differentiation medium. (B) Analysis of RIP140 mRNA expression by RT-qPCR in wild-type (WT) and E2F1
2/2
MEFs. Quantification were performed at the same times of adipocyte differentiation as in panel A. Data are expressed as percent of the values
obtained at day 0. Statistical analysis was performed using the Student t test (**p,0.005).
doi:10.1371/journal.pone.0035839.g007
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More recently, its implication in different metabolic processes
including lipid and adipocyte metabolism or glucose homeostasis
has been reported [14]. Our data suggest that RIP140 might play
a role as an E2F1 target gene in the control of adipocyte
differentiation (Figure 7). Further work will be necessary to
precisely define the role of RIP140 in E2F biological activities.
This will require in particular the phenotypic analysis of transgenic
mice with combined altered expression of E2F1 and RIP140.
In conclusion, this work is the first report to provide in vitro and
in vivo evidences demonstrating that the E2F pathway exerts at
direct transcriptional control on RIP140 expression and that this
regulation may play an important role in physiological responses
to E2F1 on key processes such as proliferation, apoptosis or
differentiation which are strongly disturbed in cancer or metabolic
diseases.
Supporting Information
Figure S1 Regulation of the human RIP140 promoter by
E2F1. (A and B) MCF-7 cells were transiently transfected with the
different human RIP140 promoter reporter plasmids (RIP900,
DPAc or DPSc) together or not (Ctrl) with expression vectors for
E2F1 and DP1. Relative luciferase activities are expressed as
percent of control and are the mean (6SD) of several independent
experiments (n=5). (C) MCF-7 cells were transiently transfected
with the human RIP900 reporter plasmids together with
expression vectors for E2F1 in the presence or absence of DP1.
Relative luciferase activities are expressed as percent of control
and are the mean (6SD) of several independent experiments
(n=10). The paired t-test was used for statistical analysis.
(TIF)
Figure S2 Effect of the E2F1 mutant (E132) on the
human RIP140 and cyclin E promoters. (A) MCF-7 cells
were transiently transfected with the human RIP140 or cyclin E
promoter reporter plasmids (25 ng) together with expression
vectors for E2F1wt or E132 mutant and DP1 (25 ng each).
Relative luciferase activity was normalized with renilla luciferase
activity as described in Materials and Methods. The values are
expressed as percent of control and are the mean (6SD) of
triplicate. The Student t-test was used for statistical analysis. (B)
The expression of the different plasmids used in panel A was
controlled by Western-blot as described in Material and Methods.
All the tracks shown are from the same western-blot but the third
track (E132) has been cut and paste to generate the Figure.
(TIF)
Figure S3 Effect of activator E2Fs and DP1 on the
murine RIP140 promoter. (A) MCF-7 cells were transiently
transfected with the murine RIP140 promoter reporter plasmids
(25 ng) together with expression vectors for E2F1, E2F2, E2F3
and DP1 (25 ng each). Results are expressed as described in legend
of Figure S2A (n=3). The values are expressed as percent of
control. (B) (C) The expression of DP1 and that of the three E2F
plasmids used in panel A was controlled by Western-blot as
described in Material and Methods.
(TIF)
Figure S4 Binding of E2F4 on the distal site of the
RIP140 promoter. (A) Electromobility shift assay was used to
analyze E2F1/DP1 or E2F4/DP1 binding on the adenoviral E2F
response element (Ad2E2F) or on the E2Fa site of the RIP140
promoter (see Figure 1). (B) ChIP experiments using immunopre-
cipitation (IP) of E21and E2F4 on the E2Fa site of the human
RIP140 promoter. Data are expressed as percent of the PCR
signal obtained with the amount of chromatin used for IP (input).
Negative control of IP was done using an isotype-matched mAb.
(C) MCF-7 cells were transiently transfected with the human and
mutant DPAc RIP140 promoter reporter plasmids (25 ng)
together with expression vectors for E2F1 and DP1 (25 ng each)
and increasing amounts of E2F4 (0/5/50 ng). Relative luciferase
activity was normalized with renilla luciferase activity as described
in Materials and Methods, and is the mean (6SD) of triplicate.
The values are expressed as a percentage of the activity obtained
with control.
(TIF)
Figure S5 Conservation of the NRIP1 promoter se-
quence among mammals. The NRIP1 promoter regions of
six mammalian species (from exon 1 b up to about 1 kbp) have
been aligned using the Multalin program (hosted at http://
multalin.toulouse.inra.fr/multalin/). Genome assembly used for
each species were Homo sapiens (hg19), Pan troglodytes
(panTro3), Bos taurus (bosTau6), Oryctolagus cuniculus (ory-
Cun2), Mus musculus (mm9), and Ratus norvegicus (rn4) as
indicated at the left of the aligned sequences that were extracted
from the UCSC genome browser (http://genome.ucsc.edu/).
Localization of putative E2F and Sp1 transcription binding sites
was performed using MathInspector pattern search program from
Genomatix (http://www.genomatix.de). E2F and Sp1 binding
sites are shown in grey and white boxes respectively, with names
above the sequence according to Figure 1 b and prefixed with h or
m to distinguish human and mouse sites. The ERE that we [6] and
others [7] found in both human and mouse promoters is shown as
a landmark. Coordinates shown above the sequence are global to
the alignment and are relative to the beginning of exon 1 b (large
box at the end of the alignment).
(TIF)
Table S1 Oligonucleotide sequences. The table shows the
sequences of all the oligonucleotides used in the different assays
(ChIP, gel shift assays and Q-PCR). The corresponding species
(human or mouse) is indicated as well as the orientation of
oligonucleotides i.e. sense/forward (fwd) or reverse (rev). The name
of the target (promoter, binding site or mRNA) is also presented.
(TIF)
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